Tags

Type your tag names separated by a space and hit enter

S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
Clin Cancer Res. 2001 Apr; 7(4):909-17.CC

Abstract

The lack of a standardized methodology for quantifying DNA ploidy and S-phase fraction (SPF) by flow cytometry is hindering routine use of these markers in breast cancer management. In a retrospective clinical multicenter study, we validated a standardized flow cytometry protocol. We tested 633 frozen T(1)T(2), N(0)N(1), M(0) breast tumors obtained in four institutions. Cell preparation was standardized, and precise rules for data interpretation were followed. Three SPF classes were defined on the basis of tertiles after adjustment for ploidy. DNA aneuploidy was observed in 61.0% of cases. No significant difference was observed among centers. Aneuploidy and high SPF were associated with large tumor size, node involvement, high histological grade, and hormone receptor negativity. In the overall population (median follow-up, 69 months), patients with medium and high SPF values had shorter disease-free survival (DFS) than those with low SPF values (P < 0.0001). Ploidy had no significant influence. By Cox analysis, SPF, pN, and estrogen receptor status were independent predictors of DFS (P = 0.0002, P = 0.001, and P = 0.05). In node-negative patients, SPF was the only predictor of DFS (P = 0.01), whereas in node-positive patients, the risk of relapse increased with both high SPF (P = 0.003) and estrogen receptor negativity (P = 0.004). Low SPF values distinguished grade II tumors with a particularly good outcome. Our results strongly support the use of SPF in multicenter studies and clinical trials and suggest that node-negative patients with slowly proliferating tumors do not require systemic adjuvant therapy.

Authors+Show Affiliations

Centre Paul Papin, Angers, France. a.chassevent@unimedia.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11309341

Citation

Chassevent, A, et al. "S-phase Fraction and DNA Ploidy in 633 T1T2 Breast Cancers: a Standardized Flow Cytometric Study." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 7, no. 4, 2001, pp. 909-17.
Chassevent A, Jourdan ML, Romain S, et al. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res. 2001;7(4):909-17.
Chassevent, A., Jourdan, M. L., Romain, S., Descotes, F., Colonna, M., Martin, P. M., Bolla, M., & Spyratos, F. (2001). S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 7(4), 909-17.
Chassevent A, et al. S-phase Fraction and DNA Ploidy in 633 T1T2 Breast Cancers: a Standardized Flow Cytometric Study. Clin Cancer Res. 2001;7(4):909-17. PubMed PMID: 11309341.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. AU - Chassevent,A, AU - Jourdan,M L, AU - Romain,S, AU - Descotes,F, AU - Colonna,M, AU - Martin,P M, AU - Bolla,M, AU - Spyratos,F, PY - 2001/4/20/pubmed PY - 2001/6/23/medline PY - 2001/4/20/entrez SP - 909 EP - 17 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 7 IS - 4 N2 - The lack of a standardized methodology for quantifying DNA ploidy and S-phase fraction (SPF) by flow cytometry is hindering routine use of these markers in breast cancer management. In a retrospective clinical multicenter study, we validated a standardized flow cytometry protocol. We tested 633 frozen T(1)T(2), N(0)N(1), M(0) breast tumors obtained in four institutions. Cell preparation was standardized, and precise rules for data interpretation were followed. Three SPF classes were defined on the basis of tertiles after adjustment for ploidy. DNA aneuploidy was observed in 61.0% of cases. No significant difference was observed among centers. Aneuploidy and high SPF were associated with large tumor size, node involvement, high histological grade, and hormone receptor negativity. In the overall population (median follow-up, 69 months), patients with medium and high SPF values had shorter disease-free survival (DFS) than those with low SPF values (P < 0.0001). Ploidy had no significant influence. By Cox analysis, SPF, pN, and estrogen receptor status were independent predictors of DFS (P = 0.0002, P = 0.001, and P = 0.05). In node-negative patients, SPF was the only predictor of DFS (P = 0.01), whereas in node-positive patients, the risk of relapse increased with both high SPF (P = 0.003) and estrogen receptor negativity (P = 0.004). Low SPF values distinguished grade II tumors with a particularly good outcome. Our results strongly support the use of SPF in multicenter studies and clinical trials and suggest that node-negative patients with slowly proliferating tumors do not require systemic adjuvant therapy. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/11309341/S_phase_fraction_and_DNA_ploidy_in_633_T1T2_breast_cancers:_a_standardized_flow_cytometric_study_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=11309341 DB - PRIME DP - Unbound Medicine ER -